Cetuximab

BNF:
Immune System & Malignant Disease
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED:

  • NICE TA439: cetuximab and panitumumab for previously untreated metastatic colorectal cancer.  (Decision date - May 2017).
  • NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck.  (Decision date - Oct 2017).

Do Not Prescribe (DNP): 

  • NICE TA242: Colorectal cancer (metastatic) 2nd line. Cetuximab – not recommended alone or in combination.  (Decision date - Feb 2012).

NHS England commissioned - to be used in line with NHSE commissioning intentions.

This drug can be funded through the cancer drug fund - seek advice from oncologist/haematologist
  

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app